Stockreport

A Look At Travere Therapeutics (TVTX) Valuation After FILSPARI's Landmark FDA Approval For FSGS [Yahoo! Finance]

Travere Therapeutics, Inc.  (TVTX) 
PDF Travere Therapeutics (TVTX) is back in focus after the U.S. FDA approved FILSPARI as the first and only therapy for focal segmental glomerulosclerosis in certain adults [Read more]